{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:48:26Z","timestamp":1761155306942},"reference-count":45,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T00:00:00Z","timestamp":1258934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> A filter has been developed (P\u2010Capt, MacoPharma) to remove infectious prions from red blood cells (RBCs). We sought to assess 1) its operational use, 2) the quality of filtered components, and 3) whether filtration resulted in any significant changes to blood group antigens.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> A total of 272 leukoreduced RBC units, including units processed using \u201ctop\u2010and\u2010top\u201d (TAT) and \u201cbottom\u2010and\u2010top\u201d (BAT) methods, were prion reduced using the P\u2010Capt filter. All RBCs were assessed using standard in vitro tests of RBC quality. Changes to blood group antigen expression were also investigated, including the exposure of cryptantigens and the ability of filtered RBCs to be crossmatched.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Ninety\u2010nine percent of TAT units and 58% of BAT units had a hemoglobin (Hb) content of more than 40\u2003g. Hemolysis increased immediately after filtration, but units remained within UK specification throughout storage. Prion reduction resulted in the loss of 7 to 8\u2003g of Hb and reductions in hematocrit of 6% to 9% due to the filter containing 40\u2003mL of saline, adenine, glucose, and mannitol. Other RBC quality data, including extracellular potassium, 2,3\u2010diphosphoglycerate, and adenosine triphosphate were similar to historical control data. There was no evidence of any immunologic changes of clinical relevance to the RBC membrane after filtration.<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> Prion filtration does not appear to have a detrimental effect on basic in vitro measures of RBC quality or on blood group antigens as assessed by in vitro methods. However, prion filtration using the P\u2010Capt filter results in loss of Hb.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2009.02500.x","type":"journal-article","created":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T21:47:46Z","timestamp":1259012866000},"page":"970-979","source":"Crossref","is-referenced-by-count":17,"title":["Prion reduction of red blood cells: impact on component quality"],"prefix":"10.1111","volume":"50","author":[{"given":"Michael","family":"Wiltshire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Haines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Garwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Cardigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.519"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05128-4"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00702.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-11-2897"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02719-7"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0463.2002.100112.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152520"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68930-7"},{"key":"e_1_2_8_13_2","doi-asserted-by":"crossref","unstructured":"PearsonH.CJD\u2010related disease can incubate for 50 years.BioEd Online2006; [Cited 2009 March 12]. Available from:http:\/\/www.bioedonline.org\/picks\/news.cfm?art=2623.","DOI":"10.1038\/news060619-12"},{"key":"e_1_2_8_14_2","volume-title":"CJD statistics","author":"NCJDSU","year":"2009"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15247-6"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16812-8"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01789.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40060754.x"},{"key":"e_1_2_8_21_2","volume-title":"Position statement: Position statement on TSE infectivity in blood","author":"SEAC","year":"2006"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00865.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69897-8"},{"key":"e_1_2_8_24_2","volume-title":"Guidelines for the Blood Transfusion Services in the United Kingdom","author":"UK Blood Services","year":"2005"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2004.00566.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01453.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01842.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987018.ch31"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(92)70166-7"},{"key":"e_1_2_8_30_2","volume-title":"Council of Europe: guide to the preparation, use and quality assurance of blood components","author":"Council of Europe","year":"2007"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1979.19279160297.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001051.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(03)00032-6"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00703.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.12.002"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2004.00526.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00894.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00893.x"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/tmrv.2001.22613"},{"key":"e_1_2_8_40_2","first-page":"89A","article-title":"Storage study of red blood cells treated with the MacoPharma P\u2010CAPT TM prion removal filter","volume":"47","author":"Begue S","year":"2007","journal-title":"Transfusion"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00918.x"},{"key":"e_1_2_8_42_2","first-page":"298","article-title":"Pharmacovigilance clinical studies with P\u2010Capt prion capture filter in human volunteers","volume":"95","author":"Walicka I","year":"2008","journal-title":"Vox Sang"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1977.17477216859.x"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184124"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1991.31391165172.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-0502(01)00004-0"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2009.02500.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2009.02500.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:38:31Z","timestamp":1697258311000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2009.02500.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1537-2995.2009.02500.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02500.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,28]]}}}